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BASIC SCIENCE STUDIES
Immunologic mechanisms play an important role
in the pathogenesis of atherosclerosis and of athero-
sclerotic abdominal aneurysms. Inflammatory white
blood cells (WBCs) invade the vessel wall and release
cytokines. It has been shown that the abdominal aor-
tic aneurysm (AAA) wall is able to produce inter-
leukin 6 (IL-6)1 and tumor necrosis factor (TNF-
a ).2-4 The new endovascular approach to treat AAA5
leaves the aneurysm intact with its intramural throm-
bus and induces a clot formation around the pros-
thetic device. Manipulations with introducers and
catheters inside the aortic aneurysm might also affect
the thrombus and subsequently induce microem-
bolization or macroembolization, usually, however,
without clinical consequences. Furthermore, release
of toxic products and cytokines may occur. In previ-
ous studies, we have shown that some patients treat-
ed with an endoluminal procedure developed a clini-
cal picture resembling a systemic inflammatory
response syndrome (SIRS) during and after the inser-
tion of the endovascular device,6,7 correlated to an
increased level of TNF-a , a mediator of SIRS.8 One
may speculate that cytokines present in the mural
thrombus of an AAA are released during the
endovascular procedure. The inflammatory process
recruits new WBCs, and further augmentation of the
WBC responses occurs, resulting in a cycle of recep-
tor adhesion molecule alterations, cytokine release,
inflammatory cell recruitment, and tissue damage.
This study determined in vitro whether the
thrombotic content from aortic aneurysms contains
cytokines and is able to activate WBCs.
Adverse reactions during endovascular
treatment of aortic aneurysms may be
triggered by interleukin 6 release from 
the thrombotic content
Paul Swartbol, MD, PhD, Lennart Truedsson, MD, PhD, and Lars Norgren,
MD, PhD, Lund, Sweden
Purpose: It has been shown that endovascular aortic aneurysm repair might induce a sig-
nificant inflammatory response, mainly involving tumor necrosis factor (TNF-a ) release.
This study determined in vitro whether these inflammatory responses could depend on
white blood cell (WBC) activation caused by the aneurysmal mural thrombus.
Methods: Mural thrombus specimens obtained from 10 different aortic aneurysms were
weighed, homogenized, and assayed for interleukin 1 b (IL-1 b ), interleukin 6 (IL-6),
TNF-a , and soluble TNF receptor (sTNFRI).
Results: Only high amounts of IL-6 (mean, 2973 pg/mL) were found. In contrast, after
the addition of healthy donor WBCs to the thrombus mass supernatants, elevated levels of
TNF-a (mean, 523 pg/mL) were seen. Theoretically, WBCs were stimulated by IL-6,
resulting in TNF-a release. In additional experiments, it was proven that stimulated
WBCs, induced by thrombus mass supernatants, synthesize TNF-a (mean, 796 pg/mL),
and monoclonal antibodies against IL-6, prevented such TNF- a production (mean, 62
pg/mL).
Conclusion: The biologic responses during endovascular repair may be explained by a
release of IL-6 from the aneurysmal thrombus, causing WBC stimulation and produc-
tion of TNF-a . More complex processes cannot be excluded, but the present findings
suggest that restrictions of manipulations within the aneurysm may be advisable. (J Vasc
Surg 1998;28:664-8.)
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METHODS
Specimens. Thrombotic content was obtained
from aortic aneurysms during 10 elective open aortic
aneurysm repairs and was directly stored at –80°C.
After defrosting, 1 g of each biopsy was homogen-
ized for 3 minutes with a tissue homogenizator. Then
10 mL phosphate buffered saline (PBS, 1/15
mol/L, pH 7.2) was added to the homogenized
thrombus, transferred to a 15 mL plastic tube, and
centrifuged for 5 minutes at 1100 rpm. Afterward,
each supernatant was washed 3 times in PBS, har-
vested, and stored at –80°C.
Analyses of cytokine levels in thrombus mass
supernatants. The thrombus mass supernatants
were assayed for IL-1b , IL-6, TNF-a , and soluble
TNF-a receptor (sTNFRI) with the use of enzyme-
linked immunosorbent assay (Quantikine, R&D
Systems, Minneapolis, Minn). These cytokines were
chosen because they are proinflammatory and play a
central role as mediators of the host response to
infection and injury. Furthermore, in all experi-
ments, each sample was assayed twice.
TNF- a determination after addition of
healthy donor WBCs to thrombus mass super-
natants. From healthy donors, 20 mL venous
blood was withdrawn into heparinized 10 mL tubes.
The monomorphonuclear and polymorphonuclear
cells were obtained using a single step centrifugal
procedure with a density gradient.9 The cell fraction
was diluted by 0.45% NaCl solution to restore nor-
mal osmolarity. The cells were then washed 3 times
in culture medium (RPMI 1640; GIBCO, Life
Technologies, Paisley, Scotland) and suspended in
RPMI supplemented with 10% fetal calf serum and
gentamicin (Sigma, St. Louis, Mo) to a final con-
centration of 1 · 106 cells/mL.
Then, 100 m L of the WBC suspension (cell con-
centration, 1 · 106/mL) was added to 100 m L
thrombus mass supernatant and incubated for 6
hours at 37°C, 5% CO2. Afterward, the samples
were centrifuged for 5 minutes at 3000 rpm. The
supernatant was harvested and stored at –80°C until
the TNF-a assay (Quantikine, R&D Systems).
For positive control experiments, 180 m L cell sus-
pension (cell concentration, 1 · 106/mL) was added
to 20 m L lipopolysaccharide (LPS) Escherichia coli
055:B5 (Sigma) at a final concentration of 10 m g/mL.
For negative controls, 100 m L cells was added to
100 m L PBS.
TNF- a measurements of thrombus mass
supernatant preincubated with monoclonal anti-
bodies against IL-6 (mAb-IL-6). For this experi-
ment, 90 m L thrombus mass supernatant was prein-
cubated with 10 m L mAb-IL-6 (5 m L/mL in 0.05
mol/L carbonate buffer, pH 9.8) for 30 minutes at
4°C. Then 100 m L WBC suspension (cell concentra-
tion, 1 · 106/mL) was added, incubated, and cen-
trifuged. As controls, 90 m L WBC suspension was
added to 10 m L IL-6 (concentrations used were
1000, 2000, and 4000 pg/mL) (positive controls),
and 100 m L WBC suspension was added to 100 m L
PBS (negative control).
Statistics. The cytokine concentrations are
expressed as mean ± SEM.
Fig 1. Ten infrarenal aortic thrombotic contents analyzed for cytokine levels. The cytokine
concentrations are expressed as mean ± SEM.
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RESULTS
Cytokine levels in thrombus mass super-
natant. Only high amounts of IL-6 (mean, 2973 ±
2670 pg/mL) were found in thrombus mass super-
natants (Fig 1). Screening for IL-1b , TNF- a , and
sTNFRI showed no elevated or detectable levels. The
detection limits were for IL-1 b 8 pg/mL, IL-6 15
pg/mL, TNF-a 32 pg/mL, and sTNFRI 78 pg/mL
(reference range for sTNFRI is 749–1966 pg/mL).
TNF- a measurements after addition of
healthy donor WBCs to thrombus mass super-
natants. By adding thrombus mass supernatants to
healthy donor WBCs, elevated levels of TNF-a were
recorded (mean, 523 ± 372 pg/mL) (Fig 2).
Addition of LPS (positive control) caused about 4
times higher TNF-a values.
These results indicate that the thrombus mass
supernatant stimulates WBCs to produce TNF- a .
Because high levels of IL-6 were found in the throm-
bus mass supernatants, it is most likely that this
cytokine has caused WBC activation. Therefore, the
role of IL-6 was determined by 2 more experiments.
First, the addition of 1000 pg/mL IL-6 caused a
significant release of TNF- a (mean, 796 ± 120
pg/mL), with no increase with the use of higher IL-
6 concentrations. Second, preincubation of mAb-
IL-6 with thrombus mass supernatant demonstrated
no WBC stimulation, as seen by low TNF-a levels
(62 ± 10 pg/mL), the results of which were equal to
the negative controls (Fig 2).
DISCUSSION
Sepsis, trauma, and more extensive surgical pro-
cedures cause pronounced inflammatory responses.
Cytokines such as TNF-a and IL-6 are proinflam-
matory mediators of the host response, and IL-6
release is a general finding after surgery, whereas
TNF-a release is seen only with complications. It is
well recognized that TNF- a infusions are able to
reproduce cardiovascular collapse signs,10 whereas
IL-6 may induce fever and cause acute phase protein
synthesis11.
In our early experience with endovascular treat-
ment of an aortic aneurysm, a sudden blood pressure
drop was recorded during insertion of the endovas-
cular device in a considerable number of patients.6,7
In these patients, TNF-a was detected immediately
after implantation, to a maximum of 60 minutes
later, and decreasing to zero values within 48 hours.
In contrast, conventional surgery did not cause any
TNF- a increase. IL-6 concentration increased in
both groups, significantly more during open surgery,
between 6 and 24 hours after clamping. Also, body
temperature was elevated in some patients until the
sixth postoperative day. There was no corresponding
finding during open surgery. The conclusions from
Fig 2. TNF- a measurements after addition of a, healthy donor WBCs to thrombus mass
supernatants; b, LPS to WBCs (positive control); c, PBS to WBCs (negative control); d, prein-
cubated WBCs with IL-6; e, preincubated WBCs with mAb against IL-6. All experiments were
repeated 10 times. Each sample was analyzed twice. The results are expressed as mean ± SEM.
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this study were that endovascular aortic aneurysm
repair induced a significant inflammatory response,
mainly involving TNF-a and differing from the find-
ings during open aneurysm repair7.
These findings may theoretically be explained in
various ways. One possibility is that the materials
building up the stent-supported graft may cause
inadvert reactions. In preliminary experiments on
surface adhesion molecule expression, however, the
components of the device did not cause any increased
expression of CD11b/CD18 on WBCs. Another
possibility is that manipulations inside the aortic
aneurysm may cause release of various toxic prod-
ucts. It is known that bacteria, mainly Staphylococcus
epidermidis, contaminate a proportion of aortic
aneurysm thrombi, reported at 5% to 25%.12-16
However, taking this low incidence rate into account,
it seems less reasonable to assume that bacteremia
explains our findings.
Manipulation with large introducers inside the
aneurysm might cause release of cytokines, and
endothelial damage may also take place during inser-
tion of the instruments. The concept that the mural
thrombus is an inert, “non-living” material could be
challenged. The present study showed that high
amounts of IL-6 are present in the thrombotic con-
tents of aortic aneurysms. The thrombus super-
natant also stimulated WBCs to produce TNF- a .
These results suggest that IL-6 is most likely the
main source to induce TNF-a production by WBCs.
Evidence that IL-6 plays a central role in the biolog-
ic response was found in the control experiments.
Direct WBC activation by IL-6 caused TNF- a
release and inhibition of IL-6 by monoclonal anti-
bodies demonstrated to reduce the TNF-a amount
to a level equal to negative controls (Fig 3).
Although TNF-a has been found in human athero-
mas,17,18 we did not find any increased levels in the
thrombus mass supernatants. A direct release of
TNF-a into the circulation is, therefore, less likely.
Attempts have been made to correlate isolated
TNF-a levels with patient prognosis. Although the
findings have not been consistent, circulating levels of
TNF-a have been associated with poor clinical out-
come in patients with sepsis or burns.19-22 However,
plasma levels of TNF-a have not been useful in pre-
dicting outcome when assessed in conjunction with
simple clinical and laboratory variables.23 The clinical
effects of high transient TNF- a release in patients
undergoing an endovascular AAA repair are unknown.
Theoretically, it might be possible to limit the TNF-a
release using monoclonal antibodies to adhesion mol-
ecules on WBCs. By blocking these adhesion mole-
cules, it is possible to improve survival rates and mini-
mize tissue injury associated with experimental hemor-
rhagic shock24 and sepsis.25 Moreover, a clinical
impression exists that in patients who have aneurysm
without thrombi or with only small thrombi, or when
a “non-touch” technique has been possible, the
adverse reactions (both blood pressure decreases and
cellular responses) have been limited or absent.
Therefore, the morphology of the aneurysm per se and
the experience of the surgeon may be of importance.
However, other explanations for our findings cannot
be excluded. Such possibilities include direct compres-
sion of the graft to portions of the thrombus and more
specific endothelial damage during insertion of the
device and also at the level of the nonthrombotic part
of aorta, where the proximal part of the stent graft is
pushed out into the vessel wall.
The findings of TNF- a release systemically in
our clinical studies and a primary IL-6 release from
Fig 3. Possible cause of the biological responses caused by maneuvers with introducers and
catheters into the mural thrombus of aortic aneurysm during endovascular repair. Monoclonal
antibodies against IL-6 may prevent such response.
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the thrombus mass in vitro in the present study may
not seem similar, but this is probably because only
transient IL-6 releases took place during the place-
ment of the stent grafts, and no blood samples have
been taken during this short period. This transient
IL-6 release may have activated WBCs, with a sub-
sequent upregulation of adhesion molecules and a
further activation of the cytokine cascade.
In conclusion, the mural thrombus of an aortic
aneurysm contains high amounts of IL-6. Manip-
ulation with introducers and catheters inside the
mural thrombus might release IL-6 and stimulate
WBCs to produce TNF-a , which is able to mediate
a systemic inflammatory response. To avoid or
decrease any adverse reactions during endovascular
repair of an AAA, restricted manipulations within
the vascular system seem advisable. Whether mono-
clonal antibodies can prevent inflammatory respons-
es has to be investigated.
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